Comparative Pharmacology
Head-to-head clinical analysis: ZERIT versus ZIAGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ZERIT versus ZIAGEN.
ZERIT vs ZIAGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor (NRTI); after intracellular phosphorylation to stavudine triphosphate, it competes with natural substrate deoxythymidine triphosphate for incorporation into viral DNA, causing chain termination.
Abacavir is a nucleoside reverse transcriptase inhibitor (NRTI). It is converted intracellularly to carbovir triphosphate, which competes with dGTP for incorporation into viral DNA, causing chain termination and inhibition of HIV reverse transcriptase.
Adults and adolescents (≥13 years, ≥60 kg): 40 mg orally twice daily. Adults and adolescents (≥13 years, <60 kg): 30 mg orally twice daily.
600 mg orally once daily, or 300 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life: 1.0–1.6 hours (mean 1.2 h) in adults with normal renal function; prolonged to 3.5–8.0 hours in renal impairment (CrCl <50 mL/min) requiring dose adjustment
Terminal elimination half-life: 1.5–2 hours (mean 1.7 h); intracellular triphosphate half-life: 12–15 hours, supporting once-daily dosing
Renal: approximately 67% (as unchanged drug) via glomerular filtration and active tubular secretion; biliary/fecal: minor (<10%)
Renal (approximately 82% as unchanged drug and metabolites via glomerular filtration and active tubular secretion); biliary/fecal (minor, <2%)
Category C
Category C
Antiretroviral (NRTI)
Antiretroviral (NRTI)